Overview
Hemoglobin SS disease refers to a chronic hemolytic anemia characterized by the presence of sickle cells and hemoglobin S, leading to vaso-occlusive crises and organ damage when not in acute crisis 1.Diagnosis
Clinical Presentation: Chronic anemia, intermittent pain episodes, organ dysfunction (e.g., renal, ophthalmologic) 1.
Laboratory Tests: Hemoglobin electrophoresis confirming hemoglobin S, complete blood count (CBC) showing microcytic anemia, elevated reticulocyte count 1.
Genetic Testing: Confirmation of sickle cell gene mutation 1.Management
Hydroxyurea: First-line treatment to reduce vaso-occlusive crises and improve survival (10-15 mg/kg/day) 1.
Pain Management: Analgesics for acute pain episodes, non-steroidal anti-inflammatory drugs (NSAIDs) or opioids as needed 1.
Preventive Care: Regular blood transfusions for severe anemia, folic acid supplementation 1.
Infection Prophylaxis: Penicillin prophylaxis to prevent pneumococcal infections 1.Special Populations
Pregnancy: Close monitoring for complications such as preeclampsia, sepsis, and obstetric emergencies; consider exchange transfusions for severe anemia 1.
Elderly: Increased risk of complications; tailored management focusing on organ protection and supportive care 1.
Comorbidities: Management strategies adjusted for coexisting conditions like renal failure or pulmonary complications 1.Key Recommendations
Initiate hydroxyurea for patients with hemoglobin SS disease to reduce vaso-occlusive crises and improve overall survival (Evidence: Strong) 1.
Provide penicillin prophylaxis routinely to prevent serious infections (Evidence: Strong) 1.
Tailor pain management strategies to individual patient needs, utilizing NSAIDs and opioids as appropriate (Evidence: Moderate) 1.References
1 Freedman VA, Reschovsky JD. Differences across payors in charges for agency-based home health services: evidence from the National Home and Hospice Care Survey. Health services research 1997. link